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Abstract 
Objective: To examine the evolution of the concept of the symptom cluster through literature synthesis 
and identification of knowledge gaps.  
Data source: Published literature 
Conclusion: A robust body of research has developed showing that clusters of symptoms can be 
identified empirically with modest evidence of convergence across methods.  The science would benefit 
from a coordinated effort of qualitative studies to ensure that appropriate symptoms are evaluated; 
empirical symptom cluster identification studies building upon qualitative work; and subgroup 
identification studies based on empirically defined symptom clusters.   
Implications for Nursing Practice: Work is needed to demonstrate the value of symptom cluster 
identification in guiding symptom assessment and management for cancer patients and survivors.   
Key words: symptom cluster, cancer, cancer-related symptoms 
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Following the UCSF Symptom Management Group challenge to consider the concept of the 
“symptom cluster” 1 and a state of the science lecture and paper on the symptom cluster in cancer 2, more 
recent publications have examined conceptual and methodological issues in defining symptom clusters 3-
12.  For this article, a literature search of PubMed from 2008 to 2015 was conducted and reference lists of 
relevant publications were also scanned for additional publications.  This article examines the evolution 
over the past 10 years of the concept of the symptom cluster including its definition, related theoretical 
concepts, methods of identification, stability of clusters, and identification of symptom cluster subgroups.  
The literature is synthesized and knowledge gaps are assessed as a basis for future research.  
Definition of a Symptom Cluster 
 A symptom cluster has been defined as a stable group of concurrent symptoms that are related to 
one another and distinct from other symptom clusters 13.  Symptoms in a cluster may be related through a 
common etiology or mechanism, shared variance, or a common outcome 3.  Stability of clusters could 
relate to consistency of results across clustering techniques, consistency within cancer populations, or 
stability over time.  To date, no firm conclusions have been drawn about the minimum number of 
symptoms required to form a cluster; two 1,14 or three symptoms 13 have been proposed.  The dictionary 
defines a cluster as “a number of things of the same kind held together; a group of things” 15.  The actual 
number of things required is not specified; however, the use of the word “group” carries the implication 
that it is more than two.   
However, there are arguments in favor of including symptom pairs in the definition of a symptom 
cluster.  In two clinical studies in advanced cancer patients, a gastro-intestinal symptom cluster was 
determined to be made up of two symptoms, nausea and vomiting 16,17.  In a large sample of advanced 
cancer patients, anxiety-depression was identified as a cluster across three different methods of analysis 
18,19.  Given the presence of clinically and statistically meaningful symptom pairs and the potential for 
others, it makes sense to include symptom pairs in the definition of a symptom cluster.  Another reason to 
consider symptom pairs as clusters is that the number and type of symptoms observed in a cluster is 
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reflective of the number and type of symptoms that were measured.  Measuring a larger number of related 
symptoms is likely to increase the number of symptoms included in a particular cluster.  When fewer 
symptoms are measured, a symptom pair could be a proxy for a cluster with more symptoms.  Including 
symptom pairs in the definition of a cluster provides an opportunity for a more complete description of 
symptom clusters in a specific context.   
On the other side of this issue are questions about when a symptom cluster should be considered 
complete.  As noted above, one determinant of the number of symptoms comprising a cluster is the 
number and relevance of the symptoms that are measured.  Other determinants include characteristics of 
specific cancers (such as, cough and breathlessness associated with lung cancer) 20,21, treatment modalities 
(neuropathy related to neurotoxic chemotherapy), and demographics (a body image cluster in women with 
gynecological cancers) 22.  Acknowledging these influences, experts have begun to advocate for 
agreement about a core set of symptoms to be measured across all patients23,24 as well as consideration of 
symptom clusters specific to disease 25,26 and treatment types 27.  This issue is described more fully in the 
paper on assessment of multiple co-occurring symptoms (28).   
Related Theoretical Concepts  
Across symptom management theories and models, the addition of the concepts of interaction 29, 
time 30, and mechanism 31 have proven to be important constructs guiding our scientific understanding of 
the symptom cluster.   As the science of symptom management has developed, the theories and models 
used to describe symptom clusters have expanded to incorporate explicit components.  The Theory of 
Symptom Management, proposed three components originally: the symptoms experience (addressing 
single or multiple symptoms); symptom management; and outcomes 1.  Later, this theory was expanded to 
include personal, health-illness, and environmental contexts of symptoms 32.  The Theory of Unpleasant 
Symptoms explicitly described the potential for interaction and/or synergy among multiple symptoms 29.  
Through a linear presentation of antecedents, symptoms, and outcomes, it suggested but did not explicitly 
identify a time component.  Later theoretical models expanded the time component, recognizing that 
symptoms can vary considerably over time and that variability in one symptom can influence other 
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symptoms 33,34.  One model, The Symptom Interaction Framework, explicitly identified underlying 
symptom “mechanisms” to describe alterations in process or function that could explain the presence of a 
group of symptoms 31; mechanisms could be biological, psychological, social, or behavioral.   
Methods of Identification of Symptom Clusters  
Qualitative methods allow for the exploration of the breadth and complexity of related symptoms.  
Four qualitative studies identified symptom clusters (table 1)20-22,35.  Women with gynecological cancers 
identified the symptoms of tiredness, sleeplessness, pain, depression, and weakness as the most common 
cluster experienced by all participants over one year, irrespective of treatment 22.  Three other symptom 
clusters were identified in this research, all related to chemotherapy (body image, GI and neuropathy).  In 
a longitudinal qualitative study of symptoms related to lung cancer, a subset of respiratory symptoms 
including cough, breathlessness, and fatigue were highlighted as co-occurring, influencing one another, 
and triggering other symptoms such as anxiety, depression, pain, and sleep disturbance 21.  The 
investigators did not discuss why the triggered symptoms were not part of the cluster.  In another lung 
cancer sample, the core symptoms of fatigue, pain, cough, and breathlessness were associated and 
affected one another synergistically 20.  However, the investigators noted that participants often focused 
on individual symptoms and not all symptoms were given equal weight.  In a study of chemotherapy-
induced nausea, the investigators explored the possibility that the term nausea could represent a cluster of 
symptoms35.  They concluded that the nausea experience included a cluster of symptoms that was unique 
to each individual.  Although the research identified a group of co-occurring symptoms that were 
considered separate but related to nausea (vomiting, taste changes, appetite changes, and fatigue), the 
investigators did not identify this as a symptom cluster.  More rigorous qualitative research is needed to 
ensure that symptom clusters identified through patient narrative support or challenge the current 
definition of a symptom cluster.      
 A priori Identification  
In oncology symptom research, symptom clusters have been identified using two different 
methods: 1) they have been specified “a priori”, meaning formed or conceived beforehand; or 2) they 
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have been identified using empirically, based on observation (also called “de novo”) methods 3.  A priori 
refers to symptoms selected as a cluster based on patient qualitative experience, clinical observation of 
symptom co-occurrence, or research hypotheses about the relationships among symptoms.  Symptom 
clusters identified in qualitative studies could be considered a priori if the individuals being studied 
determine the symptom selection; alternatively, they could be considered empirical if the clusters are 
derived through qualitative data analysis.   
 Quantitative research has been used to study a priori symptom clusters.  In animal studies, a 
group of behaviors (asthenia, lethargy, anorexia, weakness, and sleep disturbance) were observed that 
became known as “sickness behavior,” a syndrome thought to be the result of inflammatory processes 
induced by disease or trauma36,37.  This syndrome closely resembles the cluster of symptoms commonly 
reported by humans in the context of cancer and its treatment that may include fatigue, sleep disturbance, 
pain, depression, and mental confusion. The similarities between human symptoms and animal behaviors 
resulted in many investigations in which variations on this group of symptoms were evaluated as a priori 
symptom clusters 30,38-43.   
 A priori symptom clusters have included variations on the symptoms of fatigue, insomnia, pain, 
and depressed mood that are related to sickness behaviors (table 2)30,38-44.  Quantitative studies have 
demonstrated that these clusters meet two criteria defining a cluster: symptoms are related to one another 
and have a common influence on outcomes.  Most studies used analytic techniques such as correlation, 
path analysis, structural equation modeling, or other multivariate methods to examine the relationships 
among a group of symptoms.  One study showed that fatigue, sleep disturbance, and depression in breast 
cancer patients were correlated at each study point; and path analysis showed that symptom severity at 
each time point predicted severity of the same symptom at subsequent time points with the exception that 
earlier fatigue predicted later depression in pre-menopausal women38.  Another study examined temporal 
changes in daily symptoms (fatigue sleep disturbance, and depressed mood) selected a priori in women 
with gynecological cancers and found that greater sleep disturbance was associated earlier peak fatigue, 
and higher levels of fatigue predicted later depressed mood30.   Another study modeled fatigue as a latent 
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variable directly influenced by pain, depressed mood and insomnia43.  Results showed direct effects 
among all four symptoms as well as mediating effects: the effect of depressed mood on pain was 
mediated by insomnia; and the effect of depressed mood on fatigue was mediated by insomnia and pain. 
The effect of a presumed symptom cluster on outcomes has also been examined. For example, 
multiple regression analysis showed that the cluster of pain, fatigue, insomnia, and mood disturbance 
predicted performance status and quality of life in elderly cancer patients39.   In another study, pain, the 
cluster of fatigue, sleep disturbance, and distress in lung cancer surgery patients was negatively related to 
performance status and quality of life41.  Only one study examined how related symptoms influenced 
outcomes.  In a cross-sectional study of fatigue, insomnia, depression, and pain, a cluster was defined as 
two or more symptoms directly related to each other and indirectly related to functional performance 
(dependent variable)44.  Path analysis revealed seven indirect symptom paths to functional performance 
for pain and three paths for insomnia which the investigators characterized as synergy among symptoms.   
 Empirical Identification  
 The selection of an a priori symptom cluster does not settle the issue of the completeness of a 
cluster or the number of symptoms that are or should be included.  It is possible that other symptoms 
could be part of the cluster but were left out because of a priori selection of symptoms.  To address the 
completeness issue, an alternative approach has been to use statistical procedures to select and group 
symptoms from a larger population of symptoms.  Thus, an empirically determined symptom cluster is a 
group of symptoms derived from a larger pool of symptoms using statistical procedures (table 3)7,16,45-58.  
In this methodology, research participants rate a group of symptoms that are relevant to their situation.  A 
variety of statistical methods such as principal components analysis, common factor analysis, or cluster 
analysis are used to select clusters from the larger pool of symptoms.   
Principal Components Analysis (PCA), a type of exploratory factor analysis, is a descriptive data 
reduction method based on total variance 59 that combines a larger number of variables into smaller 
clusters that are unique and stable.  This method does not presume a theoretical basis or underlying 
connection among the symptoms within each cluster.   PCA has been the method most commonly used 
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for symptom clustering 16,19,54,58,60.  For example two studies of advanced cancer patients used PCA to 
identify symptom clusters using the Edmonton Symptom Assessment Scale (ESAS).  The first study 
identified two clusters: cluster 1 included fatigue, drowsiness, nausea, appetite, and dyspnea; cluster 2 
comprised anxiety and depression 46,47.  The second study used the ESAS measure, but supplemented it 
with 13 additional items 16, identifying four clusters: confusion, neuropsychological, anorexia-cachexia, 
and gastro-intestinal clusters.  In both studies, symptom clusters differed by age, gender, performance 
status, and/or type of cancer.  The difference between the study results could also be related to the 
symptoms measured.  A third study used PCA to identify three clusters in breast cancer patients based on 
a 32-item symptom scale: emotional, unwell, and gastro-intestinal clusters 50.  The first cluster included 
similar symptoms to the  
 Common Factor analysis (CFA) is another type of exploratory factor analysis that examines 
common variance  to determine the latent factors underlying a set of variables and develop and/or test 
hypotheses about those underlying factors 59.  Two symptom cluster studies using CFA illustrate this 
point.  In a study of breast and prostate cancer patients being treated with radiotherapy, CFA was used to 
identify symptom clusters in 160 individuals who rated 32 symptoms on the Memorial Symptom 
Assessment Scale 51.  At the midpoint of treatment, three clusters were identified: a mood-cognitive 
cluster (difficulty concentrating, feeling nervous, feeling sad, worrying, itching, feeling irritable, skin 
changes); a sickness behavior cluster (pain, lack of energy, feeling drowsy, difficulty sleeping, sweats); 
and a treatment-related cluster (urinary problems and diarrhea).  In a separate study, 282 women receiving 
chemotherapy or radiotherapy for breast cancer rated twenty symptoms 52.  Two symptom clusters were 
identified during treatment: a psycho-neurological cluster (pain, fatigue, insomnia, depressed mood, 
cognitive disturbance, and hot flashes); and an upper gastro-intestinal cluster (nausea, vomiting, 
decreased appetite).   The “sickness behavior cluster” in the breast and prostate study was similar to the 
“psycho-neurological cluster in the breast cancer study.   
Two things are noteworthy.  First, the results provided empirical validation of the “sickness 
behavior” cluster that was previously identified a priori.  Secondly, implicit in the naming of the clusters 
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was a hypothesis about the underlying mechanism.  The “sickness behavior” cluster and the “psycho-
neurological” cluster both have a hypothesized underlying mechanism of inflammation.  Although the 
symptoms included in each cluster are slightly different, some of the core symptoms are the same, lending 
modest support to the idea that there is a common mechanism underlying this group of symptoms.   
 Hierarchical Cluster analysis (HCA) is an empirical method for grouping symptoms or people 
and separating them from dissimilar groups based on measures of distance, such as Euclidian distance 61.  
In a study of 922 advanced cancer patients in a palliative medicine program, HCA was used to group 25 
symptoms 53.  Seven clusters were identified: fatigue-anorexia-cachexia, psycho-neurological, upper 
gastro-intestinal, nausea-vomiting, aero-digestive, debility, and pain clusters.  The authors argued that 
these clusters were likely to be therapeutically important because treatment of one symptom could 
influence or be influenced by another symptom in the cluster.  For example, the pain cluster included both 
pain and constipation; in advanced cancer, pain is a common problem that is often treated with opioid 
analgesics that can induce constipation.   
Stability of Symptom Clusters  
Consistency across Clustering Techniques.  In a number of studies, investigators have searched 
for symptom clusters using more than one analytic technique (table 4)19,60,62-67. Looking across clustering 
methods, one can observe both similarities and differences in the number and composition of symptom 
clusters.  A study of 1296 advanced cancer patients illustrated this point 62.  The cluster of anxiety and 
depression was identified across all three clustering methods (PCA, HCA, and CFA).  Two identical 
clusters also emerged when analyzed with PCA and HCA: one cluster included appetite, nausea, 
wellbeing, and pain; the other included fatigue, drowsiness, and dyspnea.  With CFA, only one additional 
factor emerged combining all the remaining symptoms into one factor.  The investigators concluded that 
PCA and HCA were in closer agreement than CFA.  Another example of agreement between PCA and 
HCA can be seen in a study of 400 patients with inoperable lung cancer 60.  Three symptom clusters (pain, 
mood, and respiratory) were consistent across three different methods of analysis: Pearson correlation, 
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PCA, and HCA.  Looking across studies, appetite change, proposed in qualitative research as an 
additional component of a nausea-vomiting cluster 35, was confirmed in two empirical analyses 52,56. 
Consistency within Cancer Populations.  Looking at similar cancer populations, several review 
papers concluded that there is little consistency of symptom clusters across samples.  For example, a 
review of five breast cancer studies found no cluster consistency across studies 10.  A review of 
gastrointestinal symptom clusters 11 found that 38 of 40 clusters included different symptoms; and a 
review of five lung cancer studies showed only nausea/vomiting and a respiratory cluster were common 
across two studies 9.  In a review of studies of patients with advanced disease, the authors could not 
formulate a general consensus of symptom clusters due to variability in symptoms assessed, assessment 
measures used, analytic methods, and patient demographics 12.   
Stability over Time   
Over the past decade, evidence has accumulated in support of the stability of symptom clusters 
over time.  Symptoms evaluated with exploratory factor analysis at the middle, end, and 1 month after 
radiotherapy for breast or prostate cancer showed four relatively similar symptom clusters across time 
points: mood-cognitive; treatment-related; sickness-behavior; and pain 51.  For breast cancer patients 
undergoing treatment, a psycho-neurological symptom cluster was observed via common factor analysis 
prior to treatment; this cluster was repeated during treatment and a gastro-intestinal cluster was also 
observed 52.  Symptom clusters identified before treatment in women with ovarian cancer were repeated 
during chemotherapy; additional clusters were observed during treatment that could represent the short- 
and long-term effects of treatment 49.  These studies and many others provide increasing support for the 
clustering of symptoms by virtue of their concurrence and stability over time.   
Antecedents and Consequences 
A better understanding of the antecedents and consequences of a symptom cluster could inform 
our understanding of who is likely to experience specific clusters and how the clusters influence their 
quality of life. Cluster composition has been shown to differ by age and gender 47 and by performance 
status and cancer diagnosis16 in two different studies.  In contrast, another study found no differences in 
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symptom cluster composition based on demographic or clinical factors 52.  With regard to consequences 
of symptom clusters, the number of symptom clusters experienced 16 and the presence of a specific 
symptom cluster 67 were associated with survival/mortality.  In addition, more symptoms 41, more severe 
symptoms 66, and the presence of specific clusters 56 have predicted poorer quality of life. More work is 
needed to point us toward a more robust picture of the demographic and clinical context of specific 
symptom clusters as well as the likelihood that specific clusters influence important outcomes including 
quality of life and survival. 
Identification of Patient Subgroups with a Similar Symptom Experience 
Thus far, we have examined the way in which “symptoms” are related to one another.  An 
alternative approach is to examine differences in the symptoms experience within “subgroups” of 
individuals (table 5)68-77.  Regardless of how a symptom cluster has been determined (a priori or 
empirically), there is likely to be variability in how individuals experience the cluster.  One method of 
grouping patients is to create composite symptom scores.  Sanford and colleagues 76 selected fatigue, 
sleep disturbance, depression, anxiety, and confusion as an a priori cluster in women undergoing 
chemotherapy for breast cancer.  Participants were assigned to a symptom cluster index group based on 
the number of abnormal symptom scores at the initial assessment.  With the exception of anxiety, the 
coherence and stability of each symptom cluster group was demonstrated by similar patterns of symptom 
severity and change over time in all four symptoms.  Using a similar methodology to classify groups of 
breast cancer patients on the basis of fatigue, sleep disturbance, and depression, Liu et al 74 found a 
similar pattern of symptom cluster groups across time.   
Statistical grouping methods have also been used to evaluate groups of individuals to determine 
the prevalence and pattern of symptoms within cluster groups. Hierarchical Cluster analysis (HCA), 
previously described as a method for grouping symptoms, has also been used to identify subgroups of 
individuals with similar symptom patterns; Latent Class Analysis (LCA) has also been used for this 
purpose.  Based on HCA of the most common symptoms (fatigue, pain, dyspnea, and insomnia), lung 
cancer patients were classified into groups with mild (60%), moderate (28%) or severe (12%) composite 
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symptom scores 70.  Another study used HCA to evaluate severity patterns of the psycho-neurological 
symptom cluster (including fatigue, insomnia, pain, depressed mood, and cognitive disturbance) in breast 
cancer patients to identify four groups: all low symptoms (26%), all high symptoms (24%), low pain-high 
fatigue (19%), and high pain (30%) groups 73.  In a separate study, breast cancer patients were classified 
using LCA into subgroups based on symptoms (fatigue, insomnia, pain, and depression); subgroups 
included all low symptoms (61%), all high symptoms (7%), and low pain-high fatigue (32%) 69.  Despite 
some variation in results, these studies indicate that groups of cancer patients can be classified according 
to similarities in their experience of symptom clusters.   
Stability of Symptom Cluster Subgroups over Time 
There is some evidence that symptom cluster subgroups endure over time.  Prior to radiotherapy, 
men with prostate cancer were classified into four subgroups with similar patterns of fatigue, insomnia, 
pain, depressed mood, anxiety, and treatment-related symptoms (bowel, urinary, and sexual): all low 
symptoms; moderate treatment-related symptoms; all high symptoms; and moderately high fatigue, 
depression, and anxiety with few treatment-related symptoms 68.  Similar groupings were derived after 
treatment.  In breast cancer patients undergoing treatment, before treatment subgroups were replicated 
during treatment and two new groups emerged: high depressed mood-cognitive disturbance and high 
fatigue-insomnia groups 73. 
Antecedents and Consequences of Symptom Cluster Subgroups 
Symptom cluster subgroups were shown in one study to differ by treatment received, 
performance status, and education 73; however, another study observed no differences based on 
demographic or clinical factors 74.  Considering biomarkers, several investigators were able to 
differentiate subgroups based on the presence of rare cytokine gene alleles 69, the additive effects of five 
immune response genes 75, or cytokine levels 77.  With regard to outcomes, research has shown that 
subgroups with more severe symptom clusters had poorer quality of life 70,71, worse functional status 73, 
and increased depression and worse mental quality of life 66.  Continued work in this domain will benefit 
the identification of subgroups at high risk for potentially damaging effects on patient outcomes. 
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Synthesis and Conclusions 
Advances in Defining the Symptom Cluster 
There have been significant advances in symptom cluster science over the past decade.  With 
regard to the definition of a symptom cluster, examples in the literature of clinically meaningful symptom 
pairs such as nausea-vomiting 16,17 or anxiety-depression 18 add strength to the argument for including 
symptom pairs within the definition of the symptom cluster.  More is to be gained than lost in accepting 
the more inclusive definition.  In addition, several theoretical concepts have been incorporated into 
symptom models to guide the study of symptom clusters including evaluation of influences of  symptoms 
on one another, examination of cluster stability over time, and determination of underlying mechanisms.  
An evidence base is developing to support the relevance of these concepts to the science of symptom 
clusters. 
Advances in Research and Future Directions 
It is interesting to note that cancer patients and survivors have been able to recognize and 
articulate groups of inter-related symptoms that impacted their quality of life.  Symptom cluster science 
could benefit from more focused qualitative explorations of symptom clusters across the cancer trajectory 
from diagnosis, through treatment, and into survivorship.  Learning from patients and survivors which 
symptoms co-occur reliably, are most distressing, and/or result in the most interference with functional 
status and quality of life will better inform quantitative science by ensuring that all relevant symptoms are 
represented in models.  This will also enhance the validity of the quantitative models as representations of 
the patient-survivor experience.  It may also be useful to use qualitative research to validate statistically 
derived symptom clusters as congruent with patient symptoms experience.  
There is now a robust body of research showing that clusters of symptoms can be identified 
empirically using a variety of statistical methods.  There is modest evidence of convergence across 
empirical clustering methods applied within the same sample.  However, there is less evidence of 
convergence and validation of clusters across similar samples using the same or different analytic 
strategy.  Therefore, replication studies are needed to ensure the reproducibility and usefulness of the 
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statistically identifiedsymptom cluster in the clinical setting.  Looking across methods used in symptom 
cluster research to date, the science would benefit from a coordinated effort of qualitative studies to 
ensure that appropriate symptoms are evaluated for clustering; empirical symptom cluster identification 
studies that build upon that qualitative work; and studies identifying patient subgroups based on 
empirically defined symptom clusters.  This progression would enhance the validity and reproducibility of 
symptom cluster research. 
Scientists have explored demographic, personal, and clinical characteristics associated with 
symptom clusters and cluster subgroups.  There is also research evidence that symptom clusters influence 
clinical outcomes including quality of life and survival.  This information is important for the 
identification of symptom cluster phenotypes—that is, subgroups with similar symptom patterns, 
identifying characteristics, and probable outcomes.  Continuing work is needed to identify high risk 
groups (at risk for more severe symptoms and/or worse outcomes) that can be targeted for intervention 
development and evaluation.  Ultimately there is a need to demonstrate the value of symptom cluster 
identification in guiding symptom assessment and management for cancer patients and survivors.   
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Table 1. Identification of Symptom Clusters in Qualitative Research 
 
Authors Sample Design Method Symptom Clusters Covariates/Outcomes 
Lopez, et al. 22 10 women in 
U.K. with GYN 
cancers  
Longitudinal:  
 
Pre-treatment to 
12 months post-
treatment 
 
39 interviews 
 Content Analysis 
 
1. Tiredness, sleeplessness, pain, 
depression, weakness 
2. Hair loss, ocular changes, 
body image, identity 
experience, anxiety 
3. Nausea, appetite loss, taste 
changes, bowel function, 
weight changes, distress 
4. Numbness-tingling in hands 
and feet, restlessness, 
sleeplessness, depression 
Physical symptoms interrelated with 
depression, uncertainty, body image, 
and identity as cancer patient. 
Maguire, et al. 
20  
10 individuals in 
U.K. with 
advanced lung 
cancer reporting 
3+ symptoms 
Longitudinal: 
 
2 interviews 3-5 
weeks apart 
Interpretative 
Phenomenological 
Analysis (IPA) 
1. Cough, pain, insomnia 
2. Breathlessness, appetite loss, 
weight loss 
3. Fatigue, nocturia, disrupted 
sleep 
Detrimental impact on physical 
functioning  
Molassiotis, et 
al.21   
17 individuals in 
U.K. with 
inoperable lung 
cancer  
Longitudinal:  
 
Beginning of 
treatment, 3, 6, 12 
months 
IPA 1. Cough, breathlessness, fatigue, 
sleep disturbance, anxiety 
 Cough associated with 
sleeplessness;  
 Sleeplessness triggered fatigue; 
 Coughing worsened 
breathlessness;  
 Breathlessness triggered anxiety 
Olver, et al. 35 42 cancer patients 
in Australia with 
chemotherapy-
induced nausea 
Cross-sectional Thematic analysis Separate concomitant symptoms 
experienced with nausea: 
vomiting, appetite changes, taste 
changes, fatigue 
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Table 2. A Priori Identification of Symptom Clusters in Quantitative Research 
 
Authors Sample Design Method Symptom Clusters Covariates/Patterns/Outcomes 
Cheng, et al.39 120 elderly 
Chinese cancer 
patients 
undergoing 
treatment 
Cross-sectional 
 
Symptom Distress 
Scale (SDS); 4 
symptoms 
selected for 
analysis 
Multiple Regression 
 
Independent 
variables: symptoms 
 
Dependent 
variables: functional 
status, quality of life 
Symptom cluster: pain, fatigue, 
insomnia, mood disturbance 
 20% of sample reported any 2 
symptoms; 29%; reported any 3 
symptoms;  33% reported all 4 
symptoms  
 Low to moderate correlations 
between symptom pairs 
 All 4 symptoms had independent 
effects on quality of life 
Ho, et al. 38 137 breast cancer 
patients in U.S. 
treated with 
chemotherapy 
Longitudinal:  
 
Pre-, post, and 6-8 
months 
 
Validated 
symptom scales 
Path Analysis Symptom cluster: Fatigue, sleep 
disturbance, depression 
 All symptoms were correlated at 
each time point; 
 Prior symptom severity predicted 
subsequent severity of same 
symptom. 
 In pre-menopausal women, 
baseline fatigue predicted post-
treatment depression; and post-
treatment fatigue predicted 
depression at final follow-up. 
Hoffman, et 
al.40 
80 newly 
diagnosed lung 
cancer patients in 
U.S. undergoing 
chemotherapy 
Cross-sectional 
 
Baseline 
observation 
 
Cancer Symptom 
Experience 
Inventory; 3 
symptoms 
selected for 
analysis 
Multinomial log-
linear modeling 
Symptom cluster: pain, fatigue, 
insomnia 
 3-way interaction among 
symptoms 
 Covariates of age, comorbidities, 
and stage of disease did not 
improve the model 
Jim, et al. 30 78 U.S. women 
with GYN 
cancers being 
treated with 
chemotherapy 
Longitudinal: 
 
Daily symptom 
ratings for 7 days; 
actigraph for 7 
days 
 
Latent Change 
Scores 
Symptom cluster: Fatigue, sleep 
disturbance, depressed mood 
Symptoms occurred in cascade 
pattern: 
 Higher level of sleep disturbance 
was associated with earlier peak 
of fatigue 
 Higher fatigue level was 
associated with higher subsequent 
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 depressed mood. 
Lin, et al. 41 145 Chinese lung 
cancer patients 
post-surgery 
Cross-sectional 
 
One week post-
surgery 
 
MD Anderson 
Symptom 
Inventory 
(MDASI); 4 
symptoms 
selected based on 
prevalence and 
severity 
Multiple regression 
 
Independent 
variables: symptoms 
 
Dependent variable: 
quality of life 
Symptom cluster: fatigue, pain, 
sleep disturbance, distress 
 Presence of more symptoms 
associated with poorer quality of 
life 
 In hierarchical regression, fatigue, 
sleep, and distress accounted for 
72% of variance in quality of life 
Oh, et al. 44 110 South Korean 
cancer patients 
undergoing 
treatment 
Cross-sectional 
 
Validated 
symptom scales 
Path Analysis 
 
Symptom cluster 
defined as two or 
more symptoms 
directly related to 
each other and 
indirectly related to 
outcome 
 
Dependent variable: 
functional 
performance 
Symptom cluster: pain, insomnia, 
depression, fatigue 
 7 indirect paths  between pain and 
functional performance (pain-
insomnia, pain-depression, pain-
fatigue, pain-depression-fatigue, 
pain-insomnia-depression-
fatigue) 
 3 indirect paths between insomnia 
and functioning (insomnia-
depression, insomnia-fatigue, 
insomnia-depression-fatigue) 
So, et al. 42 215 Chinese 
women 
undergoing 
treatment for 
breast cancer in 
Hong Kong 
Cross-sectional 
 
During treatment 
 
Validated 
symptom scales 
Correlation; 
Structural Equation 
Modeling (SEM) 
Symptom cluster:  
Fatigue, pain, anxiety, depression 
 Correlation among symptoms 
supported existence of symptom 
cluster 
 More severe symptoms, treatment 
with chemotherapy, and lower 
social support was associated 
with poorer quality of life 
Stepanski, et 
al.43 
11,445 U.S. 
cancer patients 
undergoing 
treatment  
Cross-sectional 
 
During treatment 
 
Patient Care 
SEM: Test sample 
and validation 
sample 
Symptom cluster:  
Fatigue, trouble sleeping, 
depressed mood, pain 
Direct effects:  
 Fatigue, modeled as a latent 
variable, was influenced by 
depressed mood, trouble sleeping, 
and pain. 
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Monitor 
 Validated 
scale with 86 
symptoms 
 4 symptoms 
included in 
analysis 
Indirect effects:  
 effect of depressed mood on pain 
mediated by trouble sleeping 
 effect of trouble sleeping on 
fatigue mediated by pain;  
 effect of depressed mood on 
fatigue mediated by trouble 
sleeping and pain. 
Cross-validation of model was 
supported by validation sample 
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Table 3. Empirical Identification of Symptom Clusters  
 
Authors Sample Design Method Description of Clusters Covariates/Patterns/Outcomes 
Brown, et al. 45 196 U.S. women 
6 months to 5 
years post-
diagnosis of Non-
small cell lung 
cancer  
Cross-sectional 
 
Lung Cancer 
Symptom Scale 
(LCS) 
Novel strategy for 
identification of 
symptom clusters 
using dummy codes 
1. 3-symptom cluster: no pattern 
of symptoms across 
participants 
2. 4-symptom cluster: fatigue, 
shortness of breath, cough, 
anorexia 
3. 5-symptom cluster: fatigue 
shortness of breath, cough, 
pain, anorexia (reported by 
64% of sample) 
4. 6-symptom cluster: 5-
symptom cluster plus 
hemoptysis 
 Depressed mood, time since 
diagnosis, number of 
comorbidities, and current 
treatment status were related to 
overall symptom severity 
Cheung, et al.46 
Cheung, et al.47 
1,366 Canadian 
patients with 
advanced cancer 
attending 
palliative care 
clinics 
Cross-sectional 
 
Edmonton 
Symptom 
Assessment Scale 
(ESAS) 
Principal 
Components 
Analysis (PCA) 
1. Fatigue, drowsiness, nausea, 
appetite, dyspnea  
2. Anxiety, depression 
 
 Clusters 1 and 2 accounted for 
45% and 10% of total variance, 
respectively;  
 Clusters differed by primary 
cancer site although cluster 2 was 
consistent across sites  
 Clusters differed by age and and 
gender: fatigue and drowsiness 
were included in cluster 1 for 
younger but not older patients; in 
men, pain was part of cluster 2; 
for women, physical and 
psychological symptoms formed 
separate clusters 
Gleason, et al. 
48 
66 U.S. patients 
newly diagnosed 
with brain tumors 
being treated with 
radiotherapy 
Longitudinal 
 
Pre-treatment, end 
of treatment 
 
FACT-Brain 
CESD-Depression 
Exploratory Factor 
Analysis (EFA) 
1. Language: difficulty reading, 
writing, finding works 
2. Mood: sadness, anxiety, 
depressed mood 
 
 A 3rd factor included only one 
symptom, so it was dropped 
 Factor structure at end of 
treatment was consistent with pre-
treatment 
 Multidimensional scaling and 
cluster analysis supported 2-
factor structure 
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Huang, et al. 49 111 Chinese 
ovarian cancer 
patients 
undergoing 
chemotherapy 
Longitudinal 
 
Pre-, during 
chemotherapy 
 
MSAS 
PCA Pre-treatment 
1. Pain-related: Pain, bloating, 
dizziness 
2. Psychological: Nervous, sad, 
anxious 
3. Menopausal: Lack of energy, 
dry mouth, difficulty sleeping, 
sweats, lack of appetite, 
irritation 
Cycle 1 
4. Gastro-intestinal: Nausea, 
vomiting, weight loss 
5. Body image: Hair loss, 
constipation 
Cycle 3 
6. Neurological: Numbness-
tingling, dizziness 
 Clusters 1, 2, and 3 were stable 
across time points 
 The addition of new symptom 
clusters may be attributed to 
short- and long-term effects of 
treatment. 
Jimenez, et al. 
16 
406 Spanish 
patients with 
advanced cancer 
enrolled in a 
palliative care 
program 
Cross-sectional 
 
ESAS; 13 single 
symptoms 
PCA 1. Confusion cluster: agitation, 
confusion, urinary 
incontinence 
2. Neuropsychological cluster: 
Anxiety, depression, insomnia 
3. Anorexia-cachexia cluster: 
Anorexia, weight loss, 
tiredness 
4. GI cluster: Nausea, vomiting 
 Symptom clusters differed by 
cancer site, gender, age, and 
performance status 
 Survival was related to the 
number of symptom clusters 
present 
Kenne 
Sarenmalm, et 
al.50 
206 Swedish 
breast cancer 
patients 
undergoing 
treatment 
Longitudinal 
 
Diagnosis, weeks 
1 and 3, 6 months 
 
MSAS 
PCA 1. Emotional: sad, nervous, 
worry, difficulty sleeping, 
quality of life 
2. Unwell: drowsy, dry mouth, 
appetite loss, irritability, 
difficulty swallowing, 
shortness of breath 
3. GI: weight loss, taste change, 
constipation, vomiting, hair 
loss, nausea 
 PCA Clusters 1 and 3 were 
consistent across all time points; 
cluster 2 was less consistent 
Kim, et al. 51 160 U.S. breast or 
prostate cancer 
patients being 
Longitudinal 
 
Pre-treatment, 
EFA Factor structure at middle of 
radiotherapy: 
1. Mood-cognitive: 
 Symptom clusters identified at 
end of treatment and one month 
later were not identical to mid-
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treated with 
radiotherapy 
middle and end of 
treatment, 1 
month later 
 
MSAS 
concentration, feeling nervous, 
sadness, worry, itching, 
irritability, skin changes 
2. Sickness behavior: pain, lack 
of energy, drowsiness, sleep 
difficulty, sweating 
3. Treatment-related: urinary 
problems, diarrhea 
treatment clusters; however, the 
mood-cognitive and sickness 
behavior clusters were very 
similar. 
Kim, et al. 52 282 U.S. breast 
cancer patients 
treated with 
chemotherapy or 
radiotherapy 
Longitudinal 
 
Pre-treatment, 
during treatment, 
end of treatment 
 
20 symptoms 
(some single 
items, some 
validated scales) 
Common Factor 
Analysis (CFA) 
Pre-treatment 
1. Psycho-neurological: 
Depressed mood, cognitive 
disturbance, fatigue insomnia, 
pain 
First follow-up 
1. Psycho-neurological (hot 
flashes added) 
2. Gastro-intestinal: nausea, 
vomiting, low appetite 
Second follow-up 
1. Psycho-neurological 
2. Gastro-intestinal 
 Clustering of symptoms was 
consistent across treatment 
trajectory 
 Demographic and clinical 
variables did not influence 
clustering 
Kirkova, et al. 7  
 
Walsh, et al. 53 
922 U.S. patients 
with advanced 
cancer in 
palliative care 
program 
 
Validation sample 
of 181 patients 
Cross-sectional 
 
25 symptoms with 
prevalence > 15% 
 
 
Hierarchical Cluster 
Analysis (HCA) 
1. Fatigue-anorexia-cachexia 
cluster: fatigue, lack of energy, 
weakness, dry mouth, 
anorexia, early satiety, taste 
change, weight loss 
2. Neuro-psychological cluster: 
sleep problems, anxiety, 
depression 
3. Upper GI cluster: dizzy spells, 
dyspepsia, belching, bloating 
4. Nausea-vomiting cluster: 
nausea, vomiting 
5. Aero-digestive cluster: 
dyspnea, cough, hoarseness, 
dysphagia 
6. Debility cluster: edema, 
confusion 
7. Pain cluster: pain, constipation 
 Kirkova: Validation study 
clusters were similar but not 
identical (8 clusters) 
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Molassiotis, et 
al.54  
143 patients in U. 
K. cancer centers 
Longitudinal 
 
Pre-treatment, 3, 
6, 12 months later 
 
MSAS 
PCA Pre-treatment: 
1. Nausea, vomiting, bloating 
2. Numbness-tingling hands, 
feet; swelling arms-legs 
3. Hair loss; do not like self 
4. Shortness of breath, cough 
5. Difficulty swallowing, weight 
loss, low appetite, vomiting, 
pain 
6. Feeling sad, worrying, 
nervous, difficulty 
concentrating, dizziness, 
drowsiness, Irritability, lack of 
energy 
At subsequent time points, PCA used 
again to determine core symptoms: 
 At 3- and 6-month assessments, 
core symptoms were maintained 
but new symptoms entered some 
clusters 
 At 12 months, clusters decreased 
in number of items 
Overall, the six clusters remained 
relatively consistent over time 
Olson, et al. 55 82 patients in 
Canada receiving 
palliative care  
Longitudinal 
 
1 month and 1 
week before death 
 
ESAS 
SEM 
 
Exogenous 
(background) 
variables: pain, 
anxiety, nausea, 
shortness of breath, 
drowsiness 
 
Endogenous 
(dependent): 
appetite, tiredness, 
depression, 
wellbeing 
Stable effects across time periods: 
 Drowsiness predicted appetite 
 Drowsiness predicted tiredness 
 Anxiety predicted depression 
 
 
Conclusion: There were different and 
changing causal structures underlying 
connections between symptoms 
Pirri, et al. 56 200 newly 
diagnosed 
Australian cancer 
patients 
undergoing 
combined 
modality 
treatment 
Longitudinal 
 
Pre-, on-, post-
treatment 
 
EORTC QLQ-
C30 
Selby quality of 
life scale 
PCA used to identify 
any symptom cluster 
that included nausea 
and vomiting 
 6-factor solution  
 Gastro-intestinal (GI) cluster 
(nausea, vomiting, appetite 
loss) at every time point 
 Controlling for covariates, GI 
cluster predicted overall quality 
of life impairment at end of 
treatment 
 The moderating effects of all 3 
symptoms on quality of life was 
stronger than any single symptom 
or symptom pair 
Skerman, et 
al.57 
219 Australian 
cancer patients 
Longitudinal 
 
CFA Over time, 5 consistent symptom 
clusters were characterized: 
 Several symptoms were 
associated with different clusters 
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being treated with 
chemotherapy 
Within 1 month of 
initiating 
chemotherapy, 6, 
12 months later 
 
Rotterdam 
Symptom 
Checklist—42 
symptoms 
1. Vasomotor: sweating, hot/cold 
spells, night sweats 
2. Oral discomforts: difficulty 
swallowing, sore throat, sore 
mouth, pain swallowing 
3. Upper gastro-intestinal/aero-
digestive discomforts: 
indigestion, heartburn, 
belching 
4. Gastro-intestinal toxicities: 
poor appetite, vomiting, 
nausea, shivering, stomach 
pain, trembling 
5. Musculoskeletal discomforts, 
lethargy: fatigue, sleepiness, 
muscle soreness, weakness 
over time: poor appetite, 
weakness, and fatigue 
 Vasomotor, oral, and 
musculoskeletal clusters were 
replicated over time, retaining 
over 75% of the original 
symptoms 
Tsai, et al. 58 427 Taiwanese 
patients with 
advanced cancer 
admitted to a 
palliative care 
unit 
Cross-sectional 
 
Upon admission 
 
Face-valid 
symptom 
reporting scale—
15 items 
PCA 1. Loss of energy: fatigue, 
weakness 
2. Poor intake: anorexia, taste 
changes, dysphagia, 
constipation, dry mouth 
3. Autonomic dysfunction: 
restlessness, heat, dizziness, 
insomnia, night sweats 
4. Aero-digestive impairment: 
nausea, vomiting, abdominal 
fullness, dyspnea 
5. Pain 
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Table 4. Comparison of Methods for Identification of Symptom Clusters 
 
Authors Sample Design Method Clusters or Subgroups Covariates/Outcomes 
Chen, E. 18 
 
Fan, G. 19 
1296 Canadian 
patients with 
advanced cancer 
referred to 
outpatient 
palliative care 
service 
Longitudinal 
 
Baseline, 1-, 2-, 4-
, 8-, and 12-weeks 
 
ESAS 
PCA, HCA, EFA Baseline: 
PCA 
1. Appetite, nausea, wellbeing, pain 
2. Fatigue, drowsiness, dyspnea 
3. Anxiety, depression 
 
EFA: 
1. Fatigue, drowsiness, dyspnea 
wellbeing, appetite, pain, nausea,  
2. Anxiety, depression 
 
HCA re-dividing cluster 1: 
1. Fatigue, drowsiness, dyspnea 
2. Appetite, nausea, wellbeing, pain 
3. Anxiety, depression 
 The number and composition 
of symptom clusters varied 
over time 
 Using the same analysis 
method, clusters were 
consistent over time 
 Symptom pairs (anxiety and 
depression; fatigue and 
drowsiness) were consistently 
in the same cluster with 
shifting of other symptoms 
over time 
 Results for PCA and HCA 
were more consistent across 
methods than EFA 
Cheville, A.63,64 
 
2405 U.S. lung 
cancer survivors 
up to 5 years 
post-diagnosis 
Longitudinal:  
1, 2, 3, 4, 5 years 
 
LCS; single items: 
sleep quality; 
emotion, social, 
cognitive 
wellbeing 
HCA, EFA, Latent 
Trait Analysis 
(LTA) 
HCA: 1-5 years 
1. Dyspnea, cough, fatigue 
 
EFA 
1.  Dyspnea, cough, fatigue 
 
LTA: 
1.  Fatigue, dyspnea, cough 
2.  Emotional wellbeing, sleep 
 
 A single symptom cluster was 
consistent across analytic 
methods 
 Presence of the symptom 
cluster, each component 
symptom, and symptom pairs 
were associated with 
decreased survival 
 Differences were small 
between the capacity of 
symptom clusters, pairs or 
individual symptoms to predict 
survival 
Henoch, I. 60 400 Swedish 
newly diagnosed 
Swedish lung 
cancer patients 
Cross-sectional 
1 month post-
diagnosis 
 
SDS, EORTC 
QLQ-C30 
(the same 11 
items from each 
Correlation, PCA, 
HCA 
Correlation: EORTC and SDS 
 
1. Pain cluster: pain, bowel, nausea, 
appetite, fatigue 
2. Mood cluster: insomnia, mood, 
concentration, outlook 
3. Respiratory cluster (SDS only): 
dyspnea, cough 
 Clusters were judged to be 
consistent across measures and 
analytic methods 
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scale)  
PCA: EORTC and SDS 
1. Pain cluster 
2. Mood cluster 
3. Respiratory cluster 
 
HCA: EORTC and SDS 
1. Mood cluster 
2. Respiratory cluster 
3. Pain cluster: pain, bowel, nausea 
4. Appetite, fatigue: closely related 
to each other and to pain cluster 
 
 
Maliski, S. 65 402 U.S. men 
with prostate 
cancer 
undergoing 
treatment 
Cross-sectional 
 
8-12 months post-
treatment 
 
PCI-SF: urinary, 
sexual, bowel 
dysfunction; 
SF-36: fatigue, 
pain, emotional 
distress  
FA, HCA FA: 
1. Fatigue, emotional distress 
2. Sexual and bowel dysfunction; 
pain 
[urinary dysfunction loaded equally 
on both factors] 
 
HCA: Subgroups 
1. Most pain, some fatigue, some 
sexual dysfunction (10%) 
2. Most urinary and sexual 
dysfunction (19%) 
3. Most fatigue, most emotional 
distress, some sexual dysfunction 
(14%) 
4. Most bowel dysfunction, some 
sexual dysfunction (10%) 
5. Minimal symptoms (48%) 
 Composition of the clusters 
was not consistent across 
analytic methods  
 
Roiland, R. A.66 192 U.S. older 
adult breast 
cancer survivors 
Cross-sectional 
 
Baseline data 
 
Symptom Bother 
Scale (37 items) 
EFA, CFA 
SEM 
1. Musculoskeletal: ache, stiffness, 
pain, joint pain, weakness, fatigue 
2. Neurocognitive: balance, 
dizziness, memory problems, 
concentration 
3. Dryness: dry skin, itching, dry 
mouth, thirst, shortness of breath 
 7-factor solution from EFA 
had adequate fit in CFA 
 All 7 clusters were associated 
with increased depression and 
poorer quality of life 
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4. Urinary: incontinence, increased 
urination, decreased sex drive, 
irritated eyes 
5. Circulatory: hand-foot swelling, 
taste or smell changes, hair 
thinning or loss, constipation, 
lymphedema, numbness 
6. Sleep: frequent wakening, early 
wakening, difficulty falling 
asleep, vaginal discharge 
7. Hormonal: mood swings, 
depression, anxiety, nightmares, 
hot flashes, headaches, vaginal 
dryness  
Wikman, A. 67 402 Swedish 
patients with 
esophageal cancer  
Cross-sectional 
 
EORTC QLQ-
OES-18  
completed 6 
months after 
surgery 
PCA, HCA 
 
 
PCA and HCA solutions were 
identical except diarrhea formed a 
single symptom cluster using HCA; 
PCA solution was accepted. 
1. Fatigue/pain—fatigue, pain, 
insomnia, dyspnea  
2. Reflux/cough—dry mouth, taste 
changes, cough, reflux  
3. Eating difficulty—appetite loss, 
dysphagia, eating difficulty, 
nausea-vomiting  
The reflux/cough and eating 
difficulty symptom clusters were 
associated with increased risk of 
mortality 
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Table 5. Empirical Identification of Symptom Cluster Subgroups  
 
Authors Sample Design Method Subgroups Covariates/Patterns/Outcomes 
Dirksen, et al. 
68 
84 U.S. men with 
prostate cancer 
treated with 
radiotherapy 
Longitudinal 
 
Pre-treatment, 
post-treatment 
 
Validated scales 
 
Cluster: fatigue, 
insomnia, pain, 
depression, 
anxiety, 
treatment-related 
(sexuality, 
urinary, and 
bowel symptoms) 
Latent Class 
Analysis (LCA) 
 
 
Pre-treatment groups: 
1. Resilient (45%)—all low 
symptoms 
2. Adjusted (41%)—high 
treatment-related symptoms; 
low insomnia, depression, 
anxiety 
3. Distressed (4%)—All high 
symptoms 
4. Emerged (10%)—High fatigue, 
depression, anxiety; low 
treatment-related symptoms 
Post-treatment groups: 
 Groups 1-3 had similar results 
 Group 4 changed to “Impacted” 
(5%)—high pain, insomnia, 
depression, urinary, bowel 
symptoms 
 All men in the emerging group 
before treatment moved to 
another group (66% moved to 
Distress). 
 Among those whose group 
changed, there was a greater 
probability of changing to a 
group with higher symptom 
levels. 
Doong, et al. 69 398 U.S. women 
with breast cancer 
about to undergo 
surgery 
Cross-sectional 
 
Pre-surgery 
 
Validated Scales 
 
Cluster: fatigue, 
pain, sleep 
disturbance, 
depressive 
symptoms 
Latent Class Profile 
Analysis (LCPA) 
 
 
1. All low symptoms (61%) 
2. All high symptoms (7%) 
3. Low pain, high fatigue (32%) 
 Rare alleles of cytokine genes 
(IL6 rs2069845, IL13 
rs1295686, TNFα rs1800610) 
had increased odds of being in 
the all-high symptoms subgroup. 
Franceschini, et 
al.70 
140 Brazilian 
Lung cancer 
patients  
Cross-sectional 
 
EORTC QLQ-
C30; symptoms 
selected for 
anlaysis: fatigue, 
HCA 1. Mild symptoms (60%) 
2. Moderate symptoms (28%) 
3. Severe symptoms (12%) 
 Subgroups with more severe 
symptoms had poorer quality of 
life 
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pain, insomnia, 
depression 
Husain, et al. 71 221 U.S. patients 
with advanced 
cancer 
Longitudinal 
 
Study entry, 
weeks 2, 4, 8, 12 
 
ESAS 
Cluster Analysis 
 
 
1.  High-- tired; Moderate-- 
drowsy, appetite, wellbeing, 
pain, depression, anxiety (25%) 
2. High-- tired; Moderate—
drowsy appetite, wellbeing; 
Low—pain, depression, anxiety 
(31%) 
3. Low—tired, drowsy, appetite, 
wellbeing, pain, depression, 
anxiety (44%)  
 Subgroup membership predicted 
quality of life over time 
 Grouping by symptom cluster 
profiles did not add predictive 
value to a widely used measure 
of performance status in 
palliative care 
Kim, et al. 72 282 U.S. breast 
cancer patients 
treated with 
chemotherapy or 
radiotherapy 
Longitudinal 
 
Pre-treatment, 
during treatment, 
end of treatment 
 
Some validated 
scales, some 
single items 
 
Cluster: 
Depressed mood, 
cognitive 
disturbance, 
fatigue, insomnia, 
pain 
HCA at each time 
point 
 
Logistic regression 
 
 
Pre-treatment 
1. All low symptoms 
2. High fatigue, low pain 
3. High pain 
4. All high symptoms 
During-end of treatment 
5. High depressed mood, 
cognitive disturbance 
6. High fatigue, insomnia 
 
 Subgroup membership changed 
substantially across time except 
for group 1. 
 Subgroup 4 (reference group) 
differed from the other groups 
on baseline performance status, 
symptom burden, and treatment 
modality; this pattern was 
consistent across time. 
Kim, et al. 73 282 U.S. breast 
cancer patients 
treated with 
chemotherapy or 
radiotherapy 
Longitudinal 
 
Pre-treatment, 
during treatment, 
end of treatment 
 
Some validated 
scales, some 
single items 
 
Cluster: 
HCA using 
symptom severity 
scores across three 
time points 
 
Logistic regression 
1. Gradually increasing symptoms 
(26%) 
2. Constantly low symptoms 
(37%) 
3. Dramatic increase and decrease 
of symptoms (14%) 
4. Constantly high symptoms 
(13%) 
5. Initially high symptoms with 
dramatic decrease (10%) 
 Antecedents that distinguished 
group 4 (reference group) from 
other groups: baseline 
performance status, previous 
treatment, and education 
 Subgroup 4 had worse functional 
limitations than other groups 
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Depressed mood, 
cognitive 
disturbance, 
fatigue, insomnia, 
pain 
Liu, et al. 74 
 
 
76 U.S. women 
with breast cancer 
being treated with 
anthracycline-
based 
chemotherapy 
Longitudinal:  
 
Pre-treatment, 
during each 
treatment cycle 
for 4 cycles (7 
time points) 
 
Validated scales 
Cluster: fatigue, 
sleep disturbance, 
depression 
Mixed effects model 
 
Independent 
variables: SCI 
 
Dependent 
variables: individual 
symptom scores 
 
 
 
Symptom Cluster Index (SCI) 
groups based on scale cut-offs:   
 SCI0: no symptoms (20%) 
 SCI1: 1symptom (28%) 
 SCI2: 2 symptoms (56%) 
 SCI3: 3 symptoms (24%). 
 
 Subgroups with higher SCI prior 
to treatment had worse 
symptoms during treatment 
compared with lower SCI groups   
 Subgroups did not differ by 
demographic or clinical factors 
Reyes-Gibby, 
et al. 75 
599 U.S. newly 
diagnosed lung 
cancer patients 
Cross-sectional 
 
Prior to treatment 
 
Single items: 
 
Cluster: Pain, 
depressed mood, 
fatigue 
HCA 
Logistic regression 
 
 
1. Severe symptoms (16%) 
2. Low intensity symptoms (30%) 
3. High pain; low depressed 
mood, fatigue 
4. High fatigue; low depressed 
mood, pain 
5. High fatigue depressed mood; 
low pain 
Comparison of subgroups 1 and 2: 
Additive effect of 5 alleles predicted 
membership in high symptom group 
controlling for disease stage and sex:  
 ENOS -1474 T/A  
 IL1β T-31C  
 TNRR2 Met196 Arg 
 PTGS2 exon10+8731>C 
 IL1Orβ Lys47 Glu 
Sanford, et al.76  
 
 
80 U.S. women 
with breast cancer 
being treated with 
chemotherapy  
Longitudinal: 
 
Pre-treatment, 
cycle 4 day 1, 6 
months later 
 
Validated 
symptom scales 
Cluster: fatigue, 
sleep, depression, 
anxiety, cognitive 
impairment 
Correlation;  
Mixed effect models 
SCI groups based on scale cut-offs:   
 SCI0 (22%) 
 SCI1 (28%) 
 SCI2 (26%) 
 SCI3-5 (24%) 
 
 Fatigue, depression, cognitive 
impairment: For each symptom, 
SCI groups had similar 
trajectories with symptoms 
worsening during treatment. 
 Sleep: There was no change in 
sleep within subjects or between 
groups. 
 Anxiety:  SCI groups had similar 
trajectories with anxiety 
improving over time. 
 Higher SCI scores predicted 
poorer quality of life. 
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Starkweather, 
et al.77 
128 U.S. women 
with breast cancer 
Cross-sectional 
 
4 weeks after 
breast surgery 
before 
chemotherapy 
 
Validated scales 
 
Cluster: fatigue, 
depression, pain 
Cut-off scores, 
extreme discordant 
subgroup analysis, 
median spit 
 
 
Composite score: comparison of 
groups with scores in the top and 
bottom 20% of the sample 
 
Extreme discordant scores: all 
symptoms above cut-off 
 Using composite scores, high 
and low symptom groups 
differed on IL6 and IL7 
 Using discordant scores, groups 
differed on IL7 
 Using median split, groups 
differed on IL4 and IL5. 
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